NPPB and Saethre-Chotzen syndrome: To our knowledge, no biomarkers are routinely used in risk stratification for re-infarction, whilst only a few biomarkers such as GDF-15 or NT-proBNP are of proven prognostic relevance after ACS3,21, particularly in combination22.